IBRX · ImmunityBio, Inc.

ImmunityBio reported strong preliminary financial results for the first quarter of fiscal 2026, driven by the continued commercial adoption of ANKTIVA. Preliminary net product revenue of approximately $44.2 million represents a 168% increase compared to the same quarter in the prior year and a 15% sequential increase over Q4 2025. This growth trajectory builds on the full-year 2025 net product revenue of $113 million, which marked a 700% increase over full-year 2024. Management attributed the sustained momentum to growing physician adoption and disciplined commercial execution in the U.S. market. Unit sales volume for ANKTIVA mirrored the revenue growth with a 168% year-over-year increase. Operationally, the company highlighted the full enrollment of the pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005), with the Independent Data Monitoring Committee confirming adequate statistical power, positioning the company for a supplemental BLA submission in 2026. Additionally, NCCN Clinical Practice Guidelines were updated in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease. The company maintains a solid financial position with an estimated $380.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Management noted that ANKTIVA is now approved or authorized across five regulatory jurisdictions representing approximately 34 countries. The preliminary results remain subject to final financial closing procedures and adjustments.